1.
|
International Transporter Consortium;
Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X,
Dahlin A, Evers R, Fischer V, et al: Membrane transporters in drug
development. Nat Rev Drug Discov. 9:215–236. 2010. View Article : Google Scholar
|
2.
|
Kusuhara H and Sugiyama Y: Role of
transporters in the tissue-selective distribution and elimination
of drugs: transporters in the liver, small intestine, brain and
kidney. J Control Release. 78:43–54. 2002. View Article : Google Scholar : PubMed/NCBI
|
3.
|
Chen ZS and Tiwari AK: Multidrug
resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic
diseases. FEBS J. 278:3226–3245. 2011. View Article : Google Scholar : PubMed/NCBI
|
4.
|
Köck K, Grube M, Jedlitschky G, Oevermann
L, Siegmund W, Ritter CA and Kroemer HK: Expression of adenosine
triphosphate-binding cassette (ABC) drug transporters in peripheral
blood cells: relevance for physiology and pharmacotherapy. Clin
Pharmacokinet. 46:449–470. 2007.PubMed/NCBI
|
5.
|
Nakanishi T, Tamai I, Sai Y, Sasaki T and
Tsuji A: Carrier-mediated transport of oligopeptides in the human
fibrosarcoma cell line HT1080. Cancer Res. 57:4118–4122.
1997.PubMed/NCBI
|
6.
|
Gonzalez DE, Covitz KM, Sadee W and Mrsny
RJ: An oligo-peptide transporter is expressed at high levels in the
pancreatic carcinoma cell lines AsPc-1 and Capan-2. Cancer Res.
58:519–525. 1998.PubMed/NCBI
|
7.
|
Abe T, Unno M, Onogawa T, Tokui T, Kondo
TN, Nakagomi R, Adachi H, Fujiwara K, Okabe M, Suzuki T, et al:
LST-2, a human liver-specific organic anion transporter, determines
methotrexate sensitivity in gastrointestinal cancers.
Gastroenterology. 120:1689–1699. 2001. View Article : Google Scholar : PubMed/NCBI
|
8.
|
Bleyer WA: The clinical pharmacology of
methotrexate: new applications of an old drug. Cancer. 41:36–51.
1978. View Article : Google Scholar : PubMed/NCBI
|
9.
|
Zelcer N, Reid G, Wielinga P, Kuil A, van
der Heijden I, Schuetz JD and Borst P: Steroid and bile acid
conjugates are substrates of human multidrug-resistance protein
(MRP) 4 (ATP-binding cassette C4). Biochem J. 371:361–367. 2003.
View Article : Google Scholar : PubMed/NCBI
|
10.
|
El-Sheikh AA, van den Heuvel JJ,
Koenderink JB and Russel FG: Interaction of nonsteroidal
anti-inflammatory drugs with multidrug resistance protein (MRP)
2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J
Pharmacol Exp Ther. 320:229–235. 2007. View Article : Google Scholar : PubMed/NCBI
|
11.
|
Ogawa K, Yumoto R, Hamada N, Nagai J and
Takano M: Interaction of valproic acid and carbapenem antibiotics
with multidrug resistance-associated proteins in rat erythrocyte
membranes. Epilepsy Res. 71:76–87. 2006. View Article : Google Scholar : PubMed/NCBI
|
12.
|
Belinsky MG, Guo P, Lee K, Zhou F, Kotova
E, Grinberg A, Westphal H, Shchaveleva I, Klein-Szanto A, Gallo JM
and Kruh GD: Multidrug resistance protein 4 protects bone marrow,
thymus, spleen, and intestine from nucleotide analogue-induced
damage. Cancer Res. 67:262–268. 2007. View Article : Google Scholar : PubMed/NCBI
|
13.
|
Takeuchi A, Masuda S, Saito H, Doi T and
Inui K: Role of kidney-specific organic anion transporters in the
urinary excretion of methotrexate. Kidney Int. 60:1058–1068. 2001.
View Article : Google Scholar : PubMed/NCBI
|
14.
|
Freeman MV: The fluorometric measurement
of the absorption, distribution and excretion of single doses of
4-amino-10-methyl pteroylglutamic acid (amethopterin) in man. J
Pharmacol Exp Ther. 122:154–162. 1958.PubMed/NCBI
|
15.
|
Tocco DJ, deLuna FA, Duncan AE, Hsieh JH
and Lin JH: Interspecies differences in stereoselective protein
binding and clearance of MK-571. Drug Metab Dispos. 18:388–392.
1990.PubMed/NCBI
|
16.
|
Bore P, Bruno R, Lena N, Favre R and Cano
JP: Methotrexate and 7-hydroxy-methotrexate pharmacokinetics
following intravenous bolus administration and high-dose infusion
of methotrexate. Eur J Cancer Clin Oncol. 23:1385–1390. 1987.
View Article : Google Scholar : PubMed/NCBI
|
17.
|
Bremnes RM, Slordal L, Wist E and Aarbakke
J: Formation and elimination of 7-hydroxymethotrexate in the rat in
vivo after methotrexate administration. Cancer Res. 49:2460–2464.
1989.PubMed/NCBI
|
18.
|
Giese NA, Raykov Z, DeMartino L, Vecchi A,
Sozzani S, Dinsart C, Cornelis JJ and Rommelaere J: Suppression of
metastatic hemangiosarcoma by a parvovirus MVMp vector transducing
the IP-10 chemokine into immunocompetent mice. Cancer Gene Ther.
9:432–442. 2002. View Article : Google Scholar : PubMed/NCBI
|
19.
|
Shimada T, Yamazaki H, Mimura M, Inui Y
and Guengerich FP: Interindividual variations in human liver
cytochrome P-450 enzymes involved in the oxidation of drugs,
carcinogens and toxic chemicals: studies with liver microsomes of
30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 270:414–423.
1994.
|
20.
|
Kool M, de Haas M, Scheffer GL, Scheper
RJ, van Eijk MJ, Juijn JA, Baas F and Borst P: Analysis of
expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the
multidrug resistance-associated protein gene (MRP1), in human
cancer cell lines. Cancer Res. 57:3537–3547. 1997.PubMed/NCBI
|
21.
|
Langmann T, Mauerer R, Zahn A, Moehle C,
Probst M, Stremmel W and Schmitz G: Real-time reverse
transcription-PCR expression profiling of the complete human
ATP-binding cassette transporter superfamily in various tissues.
Clin Chem. 49:230–238. 2003. View
Article : Google Scholar
|
22.
|
Gupta S, Wulf G, Henjakovic M, Koepsell H,
Burckhardt G and Hagos Y: Human organic cation transporter 1 is
expressed in lymphoma cells and increases the susceptibility to
irinotecan and paclitaxel. J Pharmacol Exp Ther. 341:16–23. 2012.
View Article : Google Scholar : PubMed/NCBI
|
23.
|
Borowski E, Bontemps-Gracz MM and
Piwkowska A: Strategies for overcoming ABC-transporters-mediated
multidrug resistance (MDR) of tumor cells. Acta Biochim Pol.
52:609–627. 2005.PubMed/NCBI
|
24.
|
Wakamatsu T, Nakahashi Y, Hachimine D,
Seki T and Okazaki K: The combination of glycyrrhizin and
lamivudine can reverse the cisplatin resistance in hepatocellular
carcinoma cells through inhibition of multidrug
resistance-associated proteins. Int J Oncol. 31:1465–1472.
2007.
|
25.
|
Jedlitschky G, Leier I, Buchholz U,
Barnouin K, Kurz G and Keppler D: Transport of glutathione,
glucuronate, and sulfate conjugates by the MRP gene-encoded
conjugate export pump. Cancer Res. 56:988–994. 1996.PubMed/NCBI
|
26.
|
Chen ZS, Kawabe T, Ono M, Aoki S, Sumizawa
T, Furukawa T, Uchiumi T, Wada M, Kuwano M and Akiyama SI: Effect
of multidrug resistance-reversing agents on transporting activity
of human canalicular multispecific organic anion transporter. Mol
Pharmacol. 56:1219–1228. 1999.
|
27.
|
Tang F, Horie K and Borchardt RT: Are MDCK
cells transfected with the human MRP2 gene a good model of the
human intestinal mucosa? Pharm Res. 19:773–779. 2002. View Article : Google Scholar : PubMed/NCBI
|
28.
|
Reid G, Wielinga P, Zelcer N, De Haas M,
Van Deemter L, Wijnholds J, Balzarini J and Borst P:
Characterization of the transport of nucleoside analogue drugs by
the human multidrug resistance proteins MRP4 and MRP5. Mol
Pharmacol. 63:1094–1103. 2003. View Article : Google Scholar : PubMed/NCBI
|
29.
|
Hasegawa M, Kusuhara H, Adachi M, Schuetz
JD, Takeuchi K and Sugiyama Y: Multidrug resistance-associated
protein 4 is involved in the urinary excretion of
hydrochlorothiazide and furosemide. J Am Soc Nephrol. 18:37–45.
2007. View Article : Google Scholar : PubMed/NCBI
|
30.
|
Ose A, Ito M, Kusuhara H, Yamatsugu K,
Kanai M, Shibasaki M, Hosokawa M, Schuetz JD and Sugiyama Y:
Limited brain distribution of
[3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate
phosphate (Ro 64-0802), a pharmacologically active form of
oseltamivir, by active efflux across the blood-brain barrier
mediated by organic anion transporter 3 (Oat3/Slc22a8) and
multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab
Dispos. 37:315–321. 2009.
|
31.
|
Chai J, Luo D, Wu X, Wang H, He Y, Li Q,
Zhang Y, Chen L, Peng ZH, Xiao T, et al: Changes of organic anion
transporter MRP4 and related nuclear receptors in human obstructive
cholestasis. J Gastrointest Surg. 15:996–1004. 2011. View Article : Google Scholar : PubMed/NCBI
|
32.
|
Mori H, Takahashi K and Mizutani T:
Interaction between valproic acid and carbapenem antibiotics. Drug
Metab Rev. 39:647–657. 2007. View Article : Google Scholar : PubMed/NCBI
|